AXGN Axogen, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 805928 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.3%
TTM net income YoY-1,422.3%
TTM EPS YoY-1,160.0%
Revenue 3-yr CAGR20.6%
Net income 3-yr CAGR—
Margins
Gross margin74.2%
Operating margin-5.2%
Net margin-12.0%
FCF margin8.3%
EBITDA margin-2.8%
Returns
ROE-10.3%
ROA-8.3%
ROIC (approx.)-7.1%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio12.02x
Interest coverage-5.72x
Cash quality & payout
Operating cash flow / net income-0.89x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $225.21M | $187.34M | $159.01M | $138.58M | $127.36M |
| Cost of revenue | $57.85M | $45.36M | $37.14M | $29.77M | $22.93M |
| Gross profit | $167.35M | $141.98M | $121.87M | $108.81M | $104.43M |
| R&D expense | $32.88M | $27.77M | $27.34M | $25.63M | $24.18M |
| SG&A expense | $44.58M | $39.04M | $38.41M | $40.91M | $32.34M |
| Operating income | -$7.85M | -$3.29M | -$21.46M | -$29.71M | -$25.42M |
| Interest expense | $7.70M | $8.21M | $2.83M | $624,000 | $1.36M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.70M | -$9.96M | -$21.72M | -$28.95M | -$26.98M |
| EBITDA | -$1.19M | $3.18M | -$17.24M | -$26.88M | -$22.67M |
| EPS (basic) | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 |
| EPS (diluted) | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 |
| Weighted avg. shares (diluted) | 46.05M | 44.26M | 42.88M | 42.08M | 41.21M |
| Balance sheet | |||||
| Cash & equivalents | $35.55M | $33.55M | $37.03M | $21.54M | $39.01M |
| Short-term investments | $5.98M | $5.93M | $0 | $33.51M | $51.33M |
| Receivables | $26.17M | $24.11M | $25.15M | $22.19M | $18.16M |
| Inventory | $42.37M | $33.18M | $23.02M | $18.91M | $16.69M |
| Current assets | $120.42M | $99.22M | $88.00M | $98.08M | $127.05M |
| PP&E, net | $81.78M | $84.67M | $88.73M | $79.29M | $62.92M |
| Intangibles | $6.75M | $5.58M | $4.53M | $3.65M | $2.86M |
| Total assets | $221.69M | $203.73M | $196.83M | $195.39M | $208.02M |
| Current liabilities | $23.56M | $30.61M | $30.43M | $23.75M | $24.29M |
| Long-term debt | $48.39M | $47.50M | $46.60M | $45.71M | $44.82M |
| Total debt | $48.39M | $47.50M | $46.60M | $45.71M | $44.82M |
| Total liabilities | $92.84M | $99.82M | $101.16M | $94.39M | $95.47M |
| Shareholders' equity | $128.85M | $103.91M | $95.67M | $101.00M | $112.55M |
| Net debt | $12.84M | $13.94M | $9.58M | $24.18M | $5.81M |
| Shares outstanding | 47.20M | 44.15M | 43.12M | 42.45M | 41.74M |
| Cash flow statement | |||||
| Operating cash flow | $812,000 | $4.54M | -$5.72M | -$16.07M | -$13.40M |
| Capital expenditure | $3.75M | $3.10M | $13.87M | $20.08M | $27.81M |
| Free cash flow | -$2.93M | $1.43M | -$19.59M | -$36.14M | -$41.22M |
| Investing cash flow | -$5.32M | -$10.30M | $19.25M | -$3.20M | -$23.65M |
| Financing cash flow | $10.50M | $2.29M | $1.95M | $1.79M | $20.45M |
| Depreciation & amortization | $6.66M | $6.47M | $4.22M | $2.83M | $2.74M |
| Stock-based compensation | $30.11M | $15.91M | $14.42M | $15.59M | $10.92M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.